Difference between revisions of "Enzalutamide (Xtandi)"
Jump to navigation
Jump to search
m |
m |
||
| Line 16: | Line 16: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2012-08-31: [http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm317997.htm Initial approval] for the treatment of patients with metastatic castration-resistant [[prostate cancer]] who have previously received [[Docetaxel (Taxotere)|docetaxel]]. ''(Based on AFFIRM)'' |
| − | * | + | *2014-09-10: Approved for the treatment of patients with metastatic castration-resistant [[prostate cancer]] (mCRPC). ''(No longer needs to be after docetaxel; based on PREVAIL and TERRAIN)'' |
| − | * | + | *2018-07-13: Approved for patients with [[Prostate cancer|castration-resistant prostate cancer (CRPC)]]. ''(No longer needs to be metatstatic; based on PROSPER<sub>PrCA</sub>)'' |
| − | *12 | + | *2019-12-16: Approved for patients with [[Prostate cancer|metastatic castration-sensitive prostate cancer (mCSPC)]]. ''(No longer needs to be castration-resistant, if metastatic; based on ARCHES)'' |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2013-06-21: Initial marketing authorization as Xtandi |
| + | ==History of changes in Health Canada indication== | ||
| + | *2013-05-29: Initial notice of compliance | ||
==Also known as== | ==Also known as== | ||
| Line 41: | Line 43: | ||
[[Category:EMA approved in 2013]] | [[Category:EMA approved in 2013]] | ||
[[Category:FDA approved in 2012]] | [[Category:FDA approved in 2012]] | ||
| + | [[Category:Health Canada approved in 2013]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 12:21, 1 April 2023
General information
Class/mechanism: Antiandrogen; androgen receptor inhibitor (ARI) or androgen receptor signaling inhibitor (ARSI). Enzalutamide competitively inhibits testosterone from binding to the androgen receptor, interferes with translocation of the androgen receptor to the nucleus, and inhibits binding to DNA, resulting in decreased prostate cancer proliferation and cell death.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
- Enzalutamide (Xtandi) package insert[1]
- Enzalutamide (Xtandi) patient drug information (Chemocare)[4]
- Enzalutamide (Xtandi) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2012-08-31: Initial approval for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel. (Based on AFFIRM)
- 2014-09-10: Approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). (No longer needs to be after docetaxel; based on PREVAIL and TERRAIN)
- 2018-07-13: Approved for patients with castration-resistant prostate cancer (CRPC). (No longer needs to be metatstatic; based on PROSPERPrCA)
- 2019-12-16: Approved for patients with metastatic castration-sensitive prostate cancer (mCSPC). (No longer needs to be castration-resistant, if metastatic; based on ARCHES)
History of changes in EMA indication
- 2013-06-21: Initial marketing authorization as Xtandi
History of changes in Health Canada indication
- 2013-05-29: Initial notice of compliance
Also known as
- Code name: MDV3100
- Brand names: Azel, Bdenza, Bnyx, Capmide, Enzamide, Glenza, Indenza, Xtandi